Clinical Trial Update: A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients [Phase 1]

View source ↗

Summary

A Phase 1 pilot trial assessing the safety of combining sitagliptin with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C; the study was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Januvia (sitagliptin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Hepatitis C | Phase 1 | Status: TERMINATED